Brief: Aytu Biopharma Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
27/05/2022 21:59
May 27 (Reuters) - Aytu Biopharma Inc AYTU.O :
* AYTU BIOPHARMA - ON MAY 24, CO RECEIVED NOTICE OF
DELISTING OR
FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ - SEC FILING
Further company coverage: AYTU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aytu Biopharma
See all newsAytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales
Aytu Biopharma Inc expected to post a loss of 32 cents a share - Earnings Preview
Aytu BioPharma Q3 revenue falls amid EXXUA launch
Aytu BioPharma Q2 revenue beats expectations